Background
==========

Ischemic stroke can occur after cardiac arrest or cerebral arterial occlusion. It can lead to devastating complications and is a global health problem. Severe outcomes of ischemic stroke, such as severe cognitive and motor dysfunction, neurodegenerative diseases, and even sudden death, are becoming a great burden on patients' families and society \[[@b1-medscimonit-23-5277]--[@b3-medscimonit-23-5277]\]. Neuronal death is a key pathological event during ischemia-induced defects-progression \[[@b2-medscimonit-23-5277],[@b3-medscimonit-23-5277]\]. Hence, many studies focus on elucidating the mechanisms underlying ischemia-induced neuronal death and related interventions. Among them, traditional Chinese herbal medicine has been receiving increasing attention.

Tetramethylpyrazine is a biologically active alkaloid extracted from *Ephedra sinica* \[[@b4-medscimonit-23-5277]\], which has been widely used in Chinese herbal medicines for various purposes including treating cardiovascular and cerebrovascular defects, anti-oxidation, anti-fibrosis, anti-nociception, anti-inflammatory, and anti-neoplastic activity \[[@b5-medscimonit-23-5277]\]. Treating brain disorders with tetramethylpyrazine has also been reported. It can promote production of BDNF and bFGF after severe brain injury and exhibited curative effects \[[@b6-medscimonit-23-5277]\]. In an ischemia model, it also showed anti-inflammatory effects \[[@b7-medscimonit-23-5277]\]. Most importantly, tetramethylpyrazine has been used in ischemic patients and shows curative effects \[[@b8-medscimonit-23-5277]\]. However, although tetramethylpyrazine was reported to protect neurons during OGD, possibly via Cx32 \[[@b9-medscimonit-23-5277]\], the relationship between tetramethylpyrazine and the classic ischemia-induced signaling pathway is not clear.

TRPC6 (transient receptor potential cation channel, subfamily C, member 6) is a kind of non-selective cation channels permeable to Ca^2+^ and has been found in many cell types, including neurons \[[@b10-medscimonit-23-5277]--[@b13-medscimonit-23-5277]\]. It can be activated by molecules showing protective effects during ischemia, including G protein-coupled receptors (GPCR) and receptor tyrosine kinases \[[@b14-medscimonit-23-5277]--[@b17-medscimonit-23-5277]\]. *In vivo* and *in vitro* experiments both found that TRPC6 downregulation was involved in ischemic neuronal cell death, and suppression of such downregulation prevents neuronal death and ischemic brain damage \[[@b18-medscimonit-23-5277]\]. Thus, we studied whether tetramethylpyrazine can influence TRPC6 and protect neurons from ischemia-induced death.

In this study, we characterized whether and how tetramethylpyrazine could protect neurons from ischemia-induced death. We found tetramethylpyrazine can protect neurons from OGD-induced death, possibly via TRPC6. Our study provides a theoretical basis for treating ischemia with tetramethylpyrazine in clinical practice.

Material and Methods
====================

Primary rat cortical neuron culture and TRPC6 RNA interfering
-------------------------------------------------------------

Primary rat cortical neuron culture was performed as described previously \[[@b19-medscimonit-23-5277]\]. Briefly, primary cortical neurons were isolated from embryonic day 15 Sprague-Dawley rats. Meninges-free cortices were dissociated and seeded in 25-cm^2^ culture plates with equal cell numbers (1--2×10^6^ cells/ml). The neurons were maintained in neurobasal medium (NBM) with 2% B27 and 0.3 mM glutamine (Invitrogen) under humidified 95% air/5% CO~2~ at 37°C. Medium was changed every 3--4 days. We added 5 μM Cytarabine (ara-C) to kill glial cells.

Transfection was carried out following the manufacture's protocol (Nucleofector Kit, Amaxa Biosystems). Briefly, after culture medium was removed, cells were seeded at 1×10^5^ cells/well in 6-wells plates for 24 h prior to transfection. Transfection mixes were set up with 100 pmol of siRNA in 250 μl of Opti-MEM and 5 μl of Lipofectamine 2000 in 250 μl of Opti-MEM (per well). A nonsense sequence was selected as a control. Transfection mixes were added to the cells for 5 h, subsequently removed, and replaced by 2 ml of new medium. The result of gene silencing was evaluated by immunoblotting.

Oxygen-glucose deprivation (OGD) and tetramethylpyrazine treatments
-------------------------------------------------------------------

OGD was performed as previously described \[[@b20-medscimonit-23-5277]\]. Culture medium was replaced by glucose-free Earle's balanced salt solution (Sigma) gassed with nitrogen (5% CO~2~ and 95% N~2~) for 10 min. Cells were then transferred for 2 h into an anaerobic chamber filled with 5% CO~2~ and 95% N~2~ and switched back to normal culture conditions for OGD-termination \[[@b18-medscimonit-23-5277]\]. Tetramethylpyrazine (95162, Sigma) was dissolved in DMSO and added into medium at different concentrations (low, 50 μg/ml; medium, 100 μg/ml; and high, 150 μg/ml) 30 min before OGD onset and until further treatments such as PI/DAPI staining and Western blot.

Assessment of cell death
------------------------

Cell death was assessed by measuring the uptake of membrane-impermeable PI. Briefly, cells were stained with PI (10 μM) and Hoechst 33258 (10 μM; for nuclear counter-staining) for 20 min and observed and imaged with a fluorescence microscope (Eclipse 80i, Nikon). The percentage of PI-positive cells relative to DAPI-positive cells per field was counted with use of Image-J software.

Western blot
------------

Prior to lysis, cells were washed with 0.01M PBS 3 times. Lysis buffer was then added. Homogenates were incubated in ice for 30 min and centrifuged at 12 000 rpm for 10 min at 4°C. Supernatants were collected and stored at −80°C for long-term use. Protein concentration was quantified by measuring OD value after incubating with Coomassie blue (G250, Life Technoledge) and the loading amount was adjusted. Samples were electrophoresed with SDS PAGE and transferred to polyvinyl difluoride membranes (PVDF, Merck Millipore). The membranes were blocked in 5% milk for 60 min at room temperature, incubated overnight at 4°C in the primary antibodies against TRPC6 (1: 10000, Ab81111, Abcam), Caspase-3 (1: 1000, 8G109665, Cell Signaling) or GAPDH (1: 1000, Cw0266, CW Biotech), and then, after washing, in horseradish peroxidase-conjugated anti-rabbit (1: 5000, BA1054, BOSTER LTD) or anti-mouse (1: 5000, BA1050, BOSTER LTD) secondary antibodies (BOSTER Biosciences) for 60 min at room temperature. The membranes were washed with TBST 3 times for 15 min each after antibody incubation. Proteins were visualized using the BeyoECLPlus ECL system.

Statistical analysis
--------------------

Data are represented as mean ± standard error of the mean (SEM). GraphPad Prism software was used for data analysis. One-way ANOVA and *post hoc* analysis was applied to compare the significance among groups. Significance was accepted at *P*\<0.05.

Results
=======

Tetramethylpyrazine rescued OGD-induced neuronal apoptosis
----------------------------------------------------------

We first examined whether tetramethylpyrazine can protect neurons from death after OGD, in an *in vitro* ischemic model, by treating neurons with tetramethylpyrazine at different concentrations. PI staining reporting neuronal death revealed that OGD-induced neuronal death (5.33±1.45% and33.0±3.79%, P\<0.0001, [Figure 1A, 1B](#f1-medscimonit-23-5277){ref-type="fig"}) could be significantly rescued by tetramethylpyrazine in a dose-dependent manner (*P*\<0.05 between OGD and OGD+Tetramethylpyrazine, [Figure 1A, 1B](#f1-medscimonit-23-5277){ref-type="fig"}). We also characterized the expression of caspase-3, a well-known apoptotic protein, with Western blot analysis. Consistent with the effect in reducing neuronal death, tetramethylpyrazine significantly decreased the expression of caspase-3 induced by OGD (0.26±0.030 in control and 0.80±0.019 in OGD, P\<0.0001 and P\<0.05 between OGD and OGD+Tetramethylpyrazine, [Figure 1C](#f1-medscimonit-23-5277){ref-type="fig"}), indicating that tetramethylpyrazine protected neurons from OGD-induced apoptosis.

Tetramethylpyrazine attenuated the downregulating of TRPC6 induced by OGD
-------------------------------------------------------------------------

Western blot analysis showed that OGD significantly reduced the expression of TRPC6 compared with the blank control group. However, this reduction was significantly attenuated by tetramethylpyrazine in a dose-dependent manner (0.72±0.019 in control and 0.28±0.026 in OGD, P\<0.0001 and P\<0.05 between OGD and OGD+Tetramethylpyrazine groups, [Figure 2](#f2-medscimonit-23-5277){ref-type="fig"}).

Efficacy of TRPC6 RNA interfering
---------------------------------

As TRPC6 was reported to mediate OGD-induced neuronal death, we further tested whether downregulating TRPC6 attenuates the effect of tetramethylpyrazine. To accomplish this, we first tested the efficacy of an RNA interfering (RNAi) against TRPC6 with Western blot assay and found that TRPC6 protein decreased significantly after interfering (0.55±0.03 in control and 0.32±0.03 in RNAi, *P*\<0.01, [Figure 3](#f3-medscimonit-23-5277){ref-type="fig"}). The amount of TRPC6 was not significantly different between the control group and blank group (0.55±0.03 in control and 0.54±0.05 in blank transfection, *P*\>0.05, [Figure 3](#f3-medscimonit-23-5277){ref-type="fig"}).

TRPC6 downregulation abolished the protective effect of tetramethylpyrazine
---------------------------------------------------------------------------

We used TRPC6 RNAi to investigate whether TRPC6 is required in the protective effect of tetramethylpyrazine after OGD. Compared with the OGD group, the percentage of PI-positive cells ([Figure 4A, 4B](#f4-medscimonit-23-5277){ref-type="fig"}, 31.67±2.03% in OGD and 12±1.73% in OGD+Tetramethylpyrazine, P\<0.05). The expression of caspase-3 ([Figure 4C](#f4-medscimonit-23-5277){ref-type="fig"}, 0.80±0.02 in OGD and 0.42 ±0.03 in OGD+Tetramethylpyrazine, P\<0.001) was significantly reduced in the presence of tetramethylpyrazine. Such reductions were blocked after downregulating TRPC6 with TRPC6 RNAi as compared with OGD+H, and the percentage of PI-positive cells ([Figure 4A, 4B](#f4-medscimonit-23-5277){ref-type="fig"}. 12.00±1.73% in OGD+H and 30.00±2.31% in OGD+H+RNAi, P\<0.0001) and the expression of caspase-3 protein in the OGD+H+RNAi group increased significantly ([Figure 4C](#f4-medscimonit-23-5277){ref-type="fig"}. 0.42±0.029 in OGD+H and 0.78±0.042 inOGD+H+RNAi, P\<0.0001).

Discussion
==========

During ischemia and stroke, oxygen-deficiency can induce neuronal death and lead to brain damage \[[@b2-medscimonit-23-5277],[@b3-medscimonit-23-5277]\]. Using an *in vitro* assay, we showed that tetramethylpyrazine protects neurons from OGD-induced death ([Figure 1](#f1-medscimonit-23-5277){ref-type="fig"}). We then found, consistent with a previous study, that downregulating TRPC6 mimics the effect of OGD ([Figure 4](#f4-medscimonit-23-5277){ref-type="fig"}). We further found that tetramethylpyrazine inhibits TRPC6 degradation during OGD and rescues OGD-induced TRPC6 downregulation in a dose-dependent manner. Finally, we found that the protective effect of tetramethylpyrazine can be abolished after downregulating TRPC6. In light of the well-documented role of TRPC6 in OGD-induced neuronal death, our data show that tetramethylpyrazine protects neurons from OGD-induced death via attenuating TRPC6 degradation. Thus, our results suggest that tetramethylpyrazine can be used as a potent treatment of ischemia and stroke.

Our study demonstrated that tetramethylpyrazine could protect neurons from OGD-induced neuronal death. Such finding is consistent with previous work and in line with the notion that tetramethylpyrazine is beneficial for brain after injury or ischemia \[[@b9-medscimonit-23-5277],[@b21-medscimonit-23-5277]--[@b23-medscimonit-23-5277]\]. As previous studies have suggested multiple mechanisms mediating the neuroprotective effect of tetramethylpyrazine, our finding uncovered an unknown pathway mediating protective effect of tetramethylpyrazine which may be upstream of effects observed in other study since TRPC6 is a calcium channel directly related to calcium signaling modulating multiple cellular processes including survival \[[@b24-medscimonit-23-5277],[@b25-medscimonit-23-5277]\] and neurotropic factor production \[[@b26-medscimonit-23-5277],[@b27-medscimonit-23-5277]\].

TRPC6 is non-selective cation channel. Its dynamics has been shown to be essential for ischemic brain injury both *in vivo* and *in vitro*. Firstly, TRPC6 level was greatly reduced before the onset of ischemia-induced neuronal death. Secondly, ischemia-induce neuronal death can be enhanced and inhibited by blocking and activating TRPC6, respectively. Exogenous peptide blocking TRPC6 degradation can reduce infarct size and improved behavioral performance \[[@b18-medscimonit-23-5277]\]. Similar effects were also observed for OGD-induced neuronal death. Thus, TRPC6 may be a more direct and central mechanism for ischemic neuronal death. Based on these findings, our results provide new knowledge for understanding the mechanism involved in treating ischemia with tetramethylpyrazine.

In summary, our work demonstrates that tetramethylpyrazine can protect neurons from OGD-induced neuronal death via TRPC6. Since we did not identify how tetramethylpyrazine influences TRPC6, future studies are required to explore this question. Our work provides a theoretical basis for treating ischemia with tetramethylpyrazine.

Conclusions
===========

Tetramethylpyrazine can protect neurons from oxygen-glucose deprivation-induced death. Such protection is possibly mediated via TRPC6.
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![Tetramethylpyrazine rescued OGD-induced neuronal death and apoptosis. (**A, B**) Representative imaging (**A**) and statistics (**B**) showing PI and DAPI staining of neurons receiving different treatments. L, M, and H mean low-, medium-, and high-dose tetramethylpyrazine, respectively. Blank means without any treatment. Bar=100 μm. (**C**) Western blot to assay the expression of Caspase-3. \*\* *P*\<0.01, \*\*\* *P*\<0.001, *vs.* Blank; ^\#^ *P*\<0.05, ^\#\#\#^ *P*\<0.001, *vs.* OGD, n=6 mice/group.](medscimonit-23-5277-g001){#f1-medscimonit-23-5277}

![Tetramethylpyrazine rescued OGD-induced TRPC6 downregulation. H means high-dose tetramethylpyrazine. Blank means without any treatment. Western blot to assay the expression of TRPC6 protein in neurons with different treatment. \*\* *P*\<0.01, \*\*\* *P*\<0.001, *vs.* Blank; ^\#^ *P*\<0.05, ^\#\#^, *P*\<0.01, *vs.* OGD, n=6 mice/group.](medscimonit-23-5277-g002){#f2-medscimonit-23-5277}

![The efficacy of TRPC6 RNA Interfering. Western blot to test the effect of TRPC6 RNA interfering on the expression of TRPC6 protein in neurons. \*\* *P*\<0.01, *vs.* Blank or Control, n= 6 mice/group.](medscimonit-23-5277-g003){#f3-medscimonit-23-5277}

![Effects of TRPC6 RNAi on neuronal death and apoptosis induced by OGD. (**A, B**) Representative imaging (**A**) and statistics (**B**) showing PI and DAPI staining of neurons receiving different treatments. H means high-dose tetramethylpyrazine. Blank means without any treatment. Bar=100 μm. (**C**) Western blot assay of the expression of caspase-3. \* *P*\<0.05, \*\* *P*\<0.01, \*\*\* *P*\<0.001, *vs.* Blank; ^\$\$\$^, *P*\<0.001, *vs.* OGD+H+RNAi, n=6 mice/group.0](medscimonit-23-5277-g004){#f4-medscimonit-23-5277}
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